Who
Andrew Saik
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Arvinas; Director, Milestone Pharmaceuticals; EVP & Chief Financial Officer, Intercept Pharmaceuticals; Chief Financial Officer, VYNE Therapeutics; Chief Financial Officer, PDS Biotechnology; CFO, Auxilium Pharmaceuticals.
In numbers
- Trades disclosed
- 61
- Buys
- 1
- Sells
- 4
- Bought
- $58K
- Sold
- $480K
- Companies
- 6
- Companies where not an officer
- 1
- First trade
- 18 Aug 2014
- Last trade
- 24 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 24 Jun 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $46K5,696 at $8.16 | filing |
| 24 Jun 2026filed 24 Jun 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $46K5,696 at $8.16 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $111K11,139 at $9.94 | filing |
| 11 May 2026filed 13 May 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $111K11,139 at $9.94 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $61K5,134 at $11.89 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $61K5,134 at $11.89 | filing |
| 24 Jun 2025filed 24 Jun 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $43K5,700 at $7.61 | filing |
| 10 Jun 2025filed 12 Jun 2025 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 May 2025filed 13 May 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,000 at $0.00 | filing |
| 9 May 2025filed 13 May 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —59,600 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,960 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —49,092 at $0.00 | filing |
| 28 Aug 2024filed 29 Aug 2024 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 15 Jul 2024filed 17 Jul 2024 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
News
Financial Comparison: Arvinas (NASDAQ:ARVN) & Geron (NASDAQ:GERN)ARVN · tickerreport.com · 20 Oct 2026
0 headlines in the last 90 days name Andrew Saik; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.